FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q37561260> ?p ?o ?g. }

• Q37561260 description "article científic" @default.
• Q37561260 description "article scientifique" @default.
• Q37561260 description "articolo scientifico" @default.
• Q37561260 description "artigo científico" @default.
• Q37561260 description "artículu científicu espublizáu en 2016" @default.
• Q37561260 description "bilimsel makale" @default.
• Q37561260 description "scientific article published on 23 August 2016" @default.
• Q37561260 description "vedecký článok" @default.
• Q37561260 description "vetenskaplig artikel" @default.
• Q37561260 description "videnskabelig artikel" @default.
• Q37561260 description "vědecký článek" @default.
• Q37561260 description "wetenschappelijk artikel" @default.
• Q37561260 description "wissenschaftlicher Artikel" @default.
• Q37561260 description "наукова стаття, опублікована в серпні 2016" @default.
• Q37561260 description "научни чланак" @default.
• Q37561260 description "مقالة علمية نشرت في 23 أغسطس 2016" @default.
• Q37561260 name "Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes" @default.
• Q37561260 name "Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes" @default.
• Q37561260 name "Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes." @default.
• Q37561260 type Item @default.
• Q37561260 label "Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes" @default.
• Q37561260 label "Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes" @default.
• Q37561260 label "Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes." @default.
• Q37561260 prefLabel "Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes" @default.
• Q37561260 prefLabel "Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes" @default.
• Q37561260 prefLabel "Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes." @default.
• Q37561260 P1433 Q37561260-B468D820-9C80-4344-B5CE-F4383670B83B @default.
• Q37561260 P1476 Q37561260-A5F8FC60-314F-42E9-8EA3-723F03A19A5A @default.
• Q37561260 P2093 Q37561260-0035DF4C-14B3-4B79-84C6-EB87EB186800 @default.
• Q37561260 P2093 Q37561260-5921A953-E3CF-4DBE-91D2-E806DD403173 @default.
• Q37561260 P2093 Q37561260-76DB204A-9B1E-4845-8079-BEA15E1B21FE @default.
• Q37561260 P2093 Q37561260-7D554454-927B-4C17-BF32-E7D051301E87 @default.
• Q37561260 P2093 Q37561260-D1653FC5-CC50-4C46-B7BC-EFB479CE1DF6 @default.
• Q37561260 P2860 Q37561260-1E7057DC-35A9-434F-AFEF-0BE98163B78F @default.
• Q37561260 P2860 Q37561260-2591E41C-D576-48F7-A3B0-7089E2AC8227 @default.
• Q37561260 P2860 Q37561260-29B05D06-CF18-4FFA-8E42-5311247C9319 @default.
• Q37561260 P2860 Q37561260-36B8518F-6252-4FDA-AFA0-0EDE83ABA2CF @default.
• Q37561260 P2860 Q37561260-400E74C8-AF68-463A-9172-4147B3CA27F2 @default.
• Q37561260 P2860 Q37561260-45192A65-341E-494A-9AFC-5C3ADBADDAEB @default.
• Q37561260 P2860 Q37561260-499F8294-1020-487A-8F88-45C26DBD39A3 @default.
• Q37561260 P2860 Q37561260-52378B5A-243B-4B31-8E7C-2D1C7E01F8AB @default.
• Q37561260 P2860 Q37561260-64E2CB1C-F5FB-4D63-AACE-D686893BE28D @default.
• Q37561260 P2860 Q37561260-6889EFF3-5834-4AD7-85CF-885F99DA59A3 @default.
• Q37561260 P2860 Q37561260-6D87319F-ED12-4AA9-A64F-7F6D2EAD25B4 @default.
• Q37561260 P2860 Q37561260-784AB069-AD67-46EA-B2C0-C60FE86BC317 @default.
• Q37561260 P2860 Q37561260-7DF22E6E-FD01-402C-A9FA-F3D3B2E619CF @default.
• Q37561260 P2860 Q37561260-85A1A9B9-703E-485D-A2E6-7CE10C3E64DD @default.
• Q37561260 P2860 Q37561260-877B381B-CED3-4BA2-88F3-697302EDE5CD @default.
• Q37561260 P2860 Q37561260-8FA3F331-14A1-49C9-8C2C-48AB41663B12 @default.
• Q37561260 P2860 Q37561260-9D932AAF-CD0D-467C-8CC9-D8A8A23718DE @default.
• Q37561260 P2860 Q37561260-9E3EAD5E-E600-41E7-8731-2E681FE5494F @default.
• Q37561260 P2860 Q37561260-A276B734-145B-4488-A228-1A606570F12D @default.
• Q37561260 P2860 Q37561260-B31004C0-3484-4D11-B942-05D6CF91855B @default.
• Q37561260 P2860 Q37561260-B81E12D2-1C73-422E-838C-F83FC631D870 @default.
• Q37561260 P2860 Q37561260-BCC2C25A-CF43-41F8-8C57-EF0E13E7D867 @default.
• Q37561260 P2860 Q37561260-C232ADA4-06C1-4D54-8E14-5572B0C5ED9E @default.
• Q37561260 P2860 Q37561260-C255E314-3598-405C-816C-6474175817AB @default.
• Q37561260 P2860 Q37561260-C4B9E3CB-1E6A-4591-8FFD-32B9BA5A4B76 @default.
• Q37561260 P2860 Q37561260-CF38A3FF-9AF1-4D72-B36D-99E6C7F169EB @default.
• Q37561260 P2860 Q37561260-D7BA95F8-8FC8-426B-BC06-5F2968A56BCC @default.
• Q37561260 P2860 Q37561260-EE9819CB-179E-4E49-9B83-8B9EC709A562 @default.
• Q37561260 P2860 Q37561260-F0151AC7-9FE2-4FEF-9DEE-8FEDC66177DA @default.
• Q37561260 P2860 Q37561260-F8C05EBA-9585-45B8-A048-0FA7B6AAB56B @default.
• Q37561260 P2860 Q37561260-F8FC2D69-D3AD-4903-B311-1591FDEDD416 @default.
• Q37561260 P2860 Q37561260-FAA9F648-61FC-42A8-8D2F-C28AD530DDAA @default.
• Q37561260 P2860 Q37561260-FB932909-445A-4D11-8870-649FD12B79B2 @default.
• Q37561260 P2860 Q37561260-FB9EEEAF-D698-4443-AD02-601000196BB3 @default.
• Q37561260 P304 Q37561260-5CA44F6E-F45A-46C2-B7E4-ABB9B5A05058 @default.
• Q37561260 P31 Q37561260-37B0EB14-253C-4B9D-8A25-263C7A9FB1EF @default.
• Q37561260 P356 Q37561260-05FE6879-57B1-438A-8BDF-25634E537BC5 @default.
• Q37561260 P433 Q37561260-A2C8E22E-DC2D-43AC-B0D5-575B17EEC924 @default.
• Q37561260 P478 Q37561260-0F537DC7-DF8A-4722-9355-6395056FBECE @default.
• Q37561260 P50 Q37561260-A59A7FAD-A590-4D82-B9CD-D6F82DF4E817 @default.
• Q37561260 P577 Q37561260-886074DA-CBE6-4252-BA29-6B7374790401 @default.
• Q37561260 P698 Q37561260-BD3AB0DF-DE3B-455D-BDCD-5DD476667F99 @default.
• Q37561260 P921 Q37561260-2C50B6C1-A830-4228-932B-539DB7A4D169 @default.
• Q37561260 P921 Q37561260-B63E135B-2BD9-448B-BBDC-5AC32E919670 @default.
• Q37561260 P932 Q37561260-7DAF3920-96BA-4701-9E93-CE5377FE455F @default.
• Q37561260 P356 DOM.12779 @default.
• Q37561260 P698 27550386 @default.
• Q37561260 P1433 Q5270109 @default.
• Q37561260 P1476 "Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes" @default.
• Q37561260 P2093 "C David Sjöström" @default.
• Q37561260 P2093 "Eva Johnsson" @default.
• Q37561260 P2093 "Jan W Eriksson" @default.
• Q37561260 P2093 "Per Lundkvist" @default.
• Q37561260 P2093 "Sam Amini" @default.
• Q37561260 P2860 Q22253010 @default.
• Q37561260 P2860 Q24244294 @default.
• Q37561260 P2860 Q24246952 @default.
• Q37561260 P2860 Q29614889 @default.
• Q37561260 P2860 Q30905084 @default.
• Q37561260 P2860 Q34015968 @default.
• Q37561260 P2860 Q34153496 @default.
• Q37561260 P2860 Q34510307 @default.
• Q37561260 P2860 Q35677315 @default.
• Q37561260 P2860 Q35973288 @default.
• Q37561260 P2860 Q36047253 @default.
• Q37561260 P2860 Q36336020 @default.
• Q37561260 P2860 Q36584204 @default.

• next